Abstracts tagged "Renal"

Abstract Number: 2043 • ACR Convergence 2025
Renal Outcomes of Long-term Canakinumab in Patients with Adult Familial Mediterranean Fever (FMF) and Biopsy-Confirmed AA Amyloidosis
Büşra Fırlatan Yazgan¹, Gözde Sevgi Kart bayram¹, Buğu Bulat¹, Levent Kılıç¹, Tolga Yildirim², Umut Kalyoncu¹, Şule Apraş Bilgen¹, Ali İhsan Ertenli¹, Seref Rahmi Yilmaz² and Omer Karadag³, ¹Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ²Division of Nephrology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey
Background/Purpose: Canakinumab, an interleukin-1β inhibitor, has demonstrated efficacy in treating colchicine-resistant/intolerant familial Mediterranean fever (FMF). This study aims to assess the efficacy and safety of…
Abstract Number: 0665 • ACR Convergence 2025
Infusion-Related Reactions (IRRs) and Hematologic Events Associated With Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial
Richard Furie¹, Teresa Baczkowska², Amit Saxena³, Imran Hassan⁴, Bongin Yoo⁵, Ben Lanza⁶, Himanshi Sehgal⁷, Frederic Boissard⁷, Jay Garg⁵, Thomas Schindler⁷, Elsa Martins⁷, William Pendergraft⁵ and Brad Rovin⁸, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland, ³Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁴Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸The Ohio State University, Columbus, OH
Background/Purpose: The REGENCY (NCT04221477) trial demonstrated superior efficacy of obinutuzumab and standard therapy (OBI+ST) over placebo and ST (PBO+ST) in patients (pts) with active lupus…
Abstract Number: 2014 • ACR Convergence 2025
Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR < 60ml/min/1.73m2:A Post-Hoc Analysis of 24-Week Data
Yu Xue¹, Tianshu Chu², Jiankang Hu³, Wei Gou⁴, Ning Zhang⁵, Juan Li⁶, Jing Yu⁷, Rongping Li⁸, Rongbin Li⁹, Long Qian¹⁰, Xinwang Duan¹¹, Lihua Duan¹² and Hejian Zou¹, ¹Department of Rheumatology,Huashan Hospital, Fudan University, Shanghai, China, shanghai, China (People's Republic), ²Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, zhengzhou, China (People's Republic), ³Department of Rheumatology, Pingxiang People's Hospital, Pingxiang,China,, Pingxiang, China (People's Republic), ⁴Department of Rheumatology, Hebei Petro ChinaCentral Hospital, Langfang, China, Langfang, China (People's Republic), ⁵Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shengjing, China (People's Republic), ⁶The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ⁷Department of Rheumatology, The FirstAffiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), ⁸Department of Rheumatology, The First Affiliated Hospital of GannanMedical University, Ganzhou, China, Ganzhou, China (People's Republic), ⁹Department ofRheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), ¹⁰Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), ¹¹The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ¹²Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)
Background/Purpose: Approximately 70% of adults with gout have CKD (Chronic Kidney Disease) ≥stage 3 (i.e estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m2), significantly restricts treatment…
Abstract Number: 0650 • ACR Convergence 2025
Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
Brad Rovin¹, Jay Garg², Richard Furie³, Rachel Jones⁴, Amit Saxena⁵, Pasquale Esposito⁶, Elsa Martins⁷, Claire Petry⁷, Nicolas Frey⁷, Bongin Yoo², Imran Hassan⁸, Thomas Schindler⁷, Theodore Omachi⁹, William Pendergraft², Mittermayer Santiago¹⁰, Gustavo Aroca Martínez¹¹ and Ana Malvar¹², ¹The Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁵Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁶Clinica Nefrologica, Dialisi, Trapianto, Department of Internal Medicine, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁹Genentech, Inc., South San Francisco, ¹⁰Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Salvador, Bahia, Brazil, ¹¹Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, ¹²Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: The Phase III REGENCY study (NCT04221477) demonstrated superiority of obinutuzumab (OBI) over placebo (PBO) in achieving complete renal response (CRR) at Week 76 when…
Abstract Number: 1991 • ACR Convergence 2025
Co-Use of Mycophenolate Mofetil with Pegloticase Yielded Similar Clinical Outcomes as the Co-Use of Methotrexate
Tingting Zhang¹, Kenneth Saag², Yasir Qazi³, Bradley Marder⁴ and Brian Lamoreaux⁵, ¹Amgen, Inc., Thousand Oaks, ²The University of Alabama at Birmingham, Birmingham, AL, ³Keck School of Medicine Renal Transplant Program, University of Southern California, Los Angeles, CA, ⁴AMGEN, Inc, Denver, CO, ⁵Amgen, Inc., Deerfield, IL
Background/Purpose: Pegloticase significantly reduces serum uric acid (sUA) values in patients with refractory gout. Co-use of methotrexate (MTX) improves efficacy and safety of pegloticase by…
Abstract Number: 0638 • ACR Convergence 2025
Prevalence of lupus nephritis, end stage kidney disease, avascular necrosis, and mortality in systemic lupus erythematosus in the recent era
Takehiro Nakai¹, Sho Fukui², Yukihiko Ikeda³, Masei Suda⁴, Hiromichi Tamaki¹, mitsumasa kishimoto⁵ and Masato Okada⁶, ¹Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ²Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ³St Luke's international hospital in Japan, Tokyo, Japan, ⁴Suwa Central Hospital, Nagano, Japan, ⁵Kyorin University School of Medicine, Tokyo, Japan, ⁶St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease associated with an increased risk of chronic kidney disease (CKD), avascular necrosis (AVN), and mortality. Despite…
Abstract Number: 1841 • ACR Convergence 2025
Differential metabolomic signatures along lupus nephritis spectrum
Mariana Jiménez Tirado¹, karina santana², Jiram Torres Ruiz³, Jennifer Tiaré Balderas Miranda⁴, Diana Gómez-Martín⁵, José Carlos Páez Franco⁶, Nancy R Mejía Domínguez⁷, Hilda Sánchez Vidal⁶ and Imelda Cecilia Zarzoza Mendoza⁸, ¹Instituto Nacional de Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ²INCMNSZ, Ciudad de México, Federal District, Mexico, ³INCMNSZ, Mexico, Federal District, Mexico, ⁴Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ⁵INCMNSZ, Mexico city, Federal District, Mexico, ⁶Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Distrito Federal, Mexico, ⁷Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁸Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico
Background/Purpose: Lupus nephritis (LN) is a common feature in systemic lupus erythematosus (SLE) affecting up to 50% of the individuals with this disease. The gold…
Abstract Number: 0615 • ACR Convergence 2025
Systemic Lupus Erythematosus Flares in Patients with End-Stage Kidney Disease on Renal Replacement Therapy or after Transplant
Jacob Klein¹, Judith Lin¹ and Marilly Palettas², ¹Ohio State University Wexner Medical Center, Columbus, OH, ²Center for Biostatistics Ohio State University, Columbus, OH
Background/Purpose: It has been observed that systemic lupus erythematosus (SLE) activity often goes into remission in patients with end-stage kidney disease (ESKD) on dialysis or…
Abstract Number: 1835 • ACR Convergence 2025
Serum Zonulin As A Biomarker Of Renal Involvement In Systemic Lupus Erythematosus: Shedding Light On The Gut-Kidney Axis
Alessandra Milone¹, Giulio Forte², Alessia Salzillo², Barbara De Marino², Rosa Giacca², Francesco Ciccia³ and Daniele Mauro⁴, ¹University of Campania L. Vanvitelli, Naples, ²University of Campania L. Vanvitelli, Naples, Italy, ³Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy, ⁴University of Campania, Italy, Naples, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease in which lupus nephritis (LN) remains a major cause of morbidity and mortality. Zonulin, a…
Abstract Number: 0856 • ACR Convergence 2025
Integrated Single-Cell and Spatial Transcriptomics Reveal Vascular and Immune Pathogenesis in APS Nephropathy
Shuyi Yu¹, Haoyu Pan¹, Jinyi Qian¹, Xiaohan Wei², Yuying Fan¹, Zhixia Yang¹, Shiyan Gu¹, Jianzhou Wu¹, Cenyi Wang¹, Tiancheng Zhou¹ and Hui Shi³, ¹Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ²Shanghai JiaoTong University, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To elucidate the molecular and cellular mechanisms underlying antiphospholipid antibody (aPL) nephropathy using integrated single-cell and spatial transcriptomic (SP) profiling of kidney tissues.Methods: Renal…
Abstract Number: 1768 • ACR Convergence 2025
TREM-1 and TREM-2 Define Inflammatory and Protective Axes in ANCA-Associated Glomerulonephritis
Lea Dionet¹, Alexandre Lanau², Paul Breillat³, Quentin Delcros⁴, Federica Pallotti⁵, Margot Poux⁶, Pierre Isnard¹, Arthur Lavigne⁴, Xavier Puéchal⁷, alexandre karras⁸, Jean-Paul Duong⁹, Olivia Lenoir¹⁰, Pierre-Louis Tharaux¹¹ and Benjamin Terrier¹², ¹INSERM, Paris, France, ²Institut Curie, Paris, France, ³INSERM, PARIS ¹⁷, Ile-de-France, France, ⁴AP-HP, Paris, France, ⁵Internal Medicine and Clinical Immunology, Rennes, France, ⁶Université de Paris, PARIS ⁰⁴EME, France, ⁷Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁸HEGP - assistance publique hopitaux de paris, paris, France, ⁹INSERM, Paris, ¹⁰Paris Cardiovascular Research Center, Université Paris Cité, INSERM U⁹⁷⁰, Paris, France, PARIS, Ile-de-France, France, ¹¹Paris Cardiovascular Research Center, Université Paris Cité, INSERM U⁹⁷⁰, Paris, France, PARIS, France, ¹²Cochin Hospital, Paris, France
Background/Purpose: ANCA-associated vasculitis (AAV) is a small-vessel vasculitis that can lead to life-threatening renal injury. Neutrophils, monocytes and macrophages play a pivotal role not only…
Abstract Number: 0838 • ACR Convergence 2025
Complete Renal Response and Long-Term, Progression-Free Survival in Adult Patients With Lupus Nephritis: A Retrospective Cohort Study in the United States
Lisa Lindsay¹, Shu Wang², Huong Trinh¹, Yunru Huang¹, William Pendergraft¹ and Brad Rovin³, ¹Genentech, Inc., South San Francisco, CA, ²Genesis Research LLC, Hoboken, NJ, ³The Ohio State University, Columbus, OH
Background/Purpose: Complete renal response (CRR) and flare prevention, as early markers of long-term kidney survival, are important outcomes in lupus nephritis (LN) clinical trials.Methods: This…
Abstract Number: 1722 • ACR Convergence 2025
Defining Safe Hydroxychloroquine Blood Levels: Time to Switch to Precision Monitoring for Optimized Lupus Care
Shivani Garg¹, Benoit Blanchet², Yann Nguyen³, Fauzia Hollnagel⁴, Ada Clarke⁵, Michelle Petri⁶, Murray Urowitz⁷, John Hanly⁸, Caroline Gordon⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Diaz¹¹, Jorge Sanchez-Guerrero¹², Ann Clarke¹³, Sasha Bernatsky¹⁴, Daniel Wallace¹⁵, David A. Isenberg¹⁶, Anisur Rahman¹⁶, Joan Merrill¹⁷, Paul Fortin¹⁸, Dafna D. Gladman¹⁹, Ian Bruce²⁰, Ellen Ginzler²¹, Mary Anne Dooley²², Rosalind Ramsey-Goldman²³, Susan Manzi²⁴, Andreas Jönsen²⁵, Graciela Alarcón²⁶, Ronald van Vollenhoven²⁷, Cynthia Aranow²⁸, Murat Inanc²⁹, Meghan mackay³⁰, Guillermo Ruiz-Irastorza³¹, S. Sam Lim³², Murat Inac³³, Kenneth Kalunian³⁴, Søren Jacobsen³⁵, Christine Peschken¹¹, Diane Kamen³⁶, Anca Askanase³⁷, Jill Buyon³⁸, Julie Chezel⁵, Alicja Puszkiel³⁹ and Nathalie Costedoat-Chalumeau⁴⁰, ¹University of Madison, School of Medicine and Public Health, Madison, WI, ²National Referral Centre for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, Paris, France, ³Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ⁴University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ⁵Cochin Hospital, Paris, France, ⁶Johns Hopkins University School of Medicine, Timonium, MD, ⁷University of Toronto, Toronto, ON, Canada, ⁸Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ⁹Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, ¹⁰Hanyang University Medical Center, Seoul, South Korea, ¹¹University of Manitoba, Winnipeg, MB, Canada, ¹²Mount Sinai Hospital and University Health Network, Toronto, Canada, ¹³Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹⁴Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁵Cedars Sinai Medical Center, Studio City, CA, ¹⁶University College London, London, United Kingdom, ¹⁷Oklahoma Medical Research Foundation, Oklahoma, ¹⁸Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ²⁰Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom, ²¹SUNY Downstate Health Sciences University, New York, NY, ²²UNC physician network, Chapel Hill, NC, ²³Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁴Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²⁵Department of Clinical Sciences, Lund University, Lund, Sweden, ²⁶The University of Alabama at Birmingham, Oakland, CA, ²⁷Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, ²⁸Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ²⁹Istanbul University, Istanbul, Turkey, ³⁰Feinstein Institutes for Medical Research, Manhasset, NY, ³¹Biobizkaia Health Research Institute, Barakaldo, Spain, ³²Emory University School of Medicine, Atlanta, GA, ³³Istanbul University, Istanbul, ³⁴UC San Diego, La Jolla, CA, ³⁵Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁶Medical University of South Carolina, Johns Island, SC, ³⁷Columbia University Medical Center, New York, NY, ³⁸NYU Grossman School of Medicine, New York, NY, ³⁹Cochin Hospital, Paris, ⁴⁰Inserm DR Paris ⁵, Paris, France
Background/Purpose: Current guidelines recommend using hydroxychloroquine (HCQ) dose ≤5.0 mg/kg for managing SLE. However, 6-fold higher SLE flares, including those requiring hospitalizations, are noted with…
Abstract Number: 1707 • ACR Convergence 2025
Racial and Ethnic Disparities in Kidney Transplant Outcomes Among Patients With Systemic Lupus Erythematosus (SLE): A 20-Year Analysis Spanning Before and After the 2014 Kidney Allocation System Revision
Soziema Salia¹, Boniface Mensah², Ufuoma Mamoh¹, Gilava Hedayati¹, Terrylyna Baffoe-Bonnie³, Joan Morny⁴ and Christhopher Haas³, ¹MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, MD, ²MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, CA, ³MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, ⁴Piedmont Athens Regional Internal Medicine Residency Program, Athens, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of end-stage kidney disease (ESKD) in young women, particularly among racial and ethnic minorities. Kidney transplantation…
Abstract Number: 1546 • ACR Convergence 2025
Tacrolimus Versus Voclosporin for Active Lupus Nephritis: A Comparative Meta-analysis of Renal Response
Urvi Zala¹ and Rushi Patel², ¹Loyola MacNeal Hospital, Berwyn, IL, Oak Park, IL, ²Baptist Hospitals of Southeast Texas, Beumont, TX
Background/Purpose: Lupus nephritis (LN) is seen in approximately 40–60 % of patients with systemic lupus erythematosus (SLE) and contributes significantly to morbidity and mortality in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].